October 09, 2024
Boehringer Ingelheim collaborates with Circle Pharma
September 09, 2024
Zongertinib shows encouraging efficacy and tolerability profile in lung cancer patients
August 27, 2024
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC
July 29, 2024
Boehringer Ingelheim acquires Nerio Therapeutics
May 22, 2024
Partnership for first-in-class cancer and CRM treatments
February 08, 2024
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
November 22, 2023
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma
January 09, 2023
New cancer therapeutics collaboration with 3T Bio
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
September 21, 2021
Acquisition to advance cancer immunology research
September 16, 2021
Clinical collaboration with Amgen on KRAS
April 14, 2021
Expansion of Collaboration with MD Anderson to Explore KRAS and TRAILR2 Compounds in Lung Cancer
January 12, 2021
Collaboration with Enara Bio on Cancer Immunotherapies
December 10, 2020
Boehringer Ingelheim to acquire NBE-Therapeutics
December 09, 2020
Boehringer Ingelheim to acquire Labor Dr. Merk and Kollegen
December 07, 2020
Collaboration with Proxygen on Molecular Glue Degraders
October 14, 2020
Expanded alliance with OBT advances cancer immunology pipeline
September 10, 2020
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
March 16, 2020